報告摘要

The global endometriosis market was valued at USD 3,030.79 million in 2025 and is projected to reach USD 9,786.23 million by 2035. The market is expected to expand at a CAGR of 12.5% during the forecast period from 2026 to 2035, driven by rising awareness, improved diagnostic technologies, and increasing treatment adoption. Rising Adoption of Hormonal Therapies Driving Market Growth The use of hormonal therapies is rapidly increasing, which is the main factor enhancing the global endometriosis market. Besides offering pain relief, these medications can also inhibit oestrogen production and limit disease advancement, often eliminating the need for surgical procedures. The launch of more effective drugs, exemplified by AbbVie's Orilissa and Bayer's Visanne, is one of the reasons why patients from different parts of the world are more inclined to the notion of long-term treatment. Segment-wise Market Overview • NSAIDs – Widely used for temporary pelvic pain relief. • Oral Contraceptives – Commonly prescribed for hormonal symptom management. • Gonadotropin Releasing Hormone Agonists Antagonists – Effective in reducing oestrogen-driven tissue growth. • Others – Includes emerging therapies and supportive medications. • Acupuncture Therapy – Gaining attention for natural pain management. • Surgery – Preferred for severe and advanced endometriosis cases. • Hospitals & Clinics – Major centres for diagnosis and treatment. • Homecare Settings – Increasing adoption of self-managed treatment approaches. • Others – Includes specialty centres and ambulatory care facilities. Due to the presence of sophisticated healthcare infrastructure, the availability of effective reimbursement systems, and the early adoption of innovative therapies, North America accounts for the largest share of the global endometriosis treatment market, while Europe continues to grow with the help of standardized care and widespread treatment access. Similarly, healthcare investment and awareness make Asia Pacific the fastest-growing market, whereas South America and the Middle East and Africa are witnessing gradual market expansion due to improving diagnosis and increasing treatment accessibility. FDA Approval Strengthens Pfizer’s Women’s Health Portfolio In August last year, Pfizer Inc. got the nod from the US FDA for MYFEMBREE. This will be the first once-daily oral medication for moderate to severe endometriosis pain in premenopausal women. Besides this, the clinical trials Phase 3 SPIRIT involving more than 1, 200 patients saw the medication marketing pharma companies to strengthen their position in women's healthcare therapeutics with a drug that not only reduces pain significantly but also has minimal impact on bone mineral density. Rising Global Focus on Women’s Healthcare Among other things, mounting worldwide investment in women's health is a major factor helping create strong growth opportunities for the endometriosis market. Governments and healthcare organizations prioritizing reproductive health awareness, diagnosis, and treatment accessibility are coming forward to open up the market further. Greater public understanding of the disease and its long-term effects on individuals' quality of life and productivity leads to accelerated research and healthcare funding. Key Report Attributes • Market Size 2025: USD 3,030.79 Million • Market Size 2035: USD 9,786.23 Million • CAGR (2026-2035): 12.5% • Base Year: 2024 • Market Forecast Period: 2025-2035 Industry Segmentations Growth • By Treatment Type: Medication - 13.5%, Acupuncture Therapy - 5.0%. • By End User: Hospitals & Clinics - 12.0%, Homecare Settings - 14.2%.

目錄 Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ....................... 17 1.1 MARKET ATTRACTIVENESS ANALYSIS ................... 18 1.2 GLOBAL ENDOMETRIOSIS TREATMENTMARKET, BY TREATMENT TYPE ................... 19 1.3 GLOBAL ENDOMETRIOSIS TREATMENTMARKET, BY END USE .................. 20 2 MARKET INTRODUCTION .................... 22 2.1 DEFINITION ........ 22 2.2 SCOPE OF THE STUDY .......... 22 2.3 RESEARCH OBJECTIVE ........ 22 2.4 MARKET STRUCTURE .......... 23 3 RESEARCH METHODOLOGY .............. 24 3.1 OVERVIEW .......... 24 3.2 DATA FLOW ........ 26 3.2.1 DATA MINING PROCESS ......................... 26 3.3 PURCHASED DATABASE: ........................... 27 3.4 SECONDARY SOURCES: ........ 28 3.4.1 SECONDARY RESEARCH DATA FLOW: .......... 29 3.5 PRIMARY RESEARCH: ........... 30 3.5.1 PRIMARY RESEARCH DATA FLOW: ............ 31 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ...................... 32 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ..................... 32 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ......................... 33 3.6.1 REVENUE ANALYSIS APPROACH .............. 33 3.7 DATA FORECASTING............. 34 3.7.1 DATA FORECASTING TYPE ....................... 34 3.8 DATA MODELING .................... 35 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ......... 35 3.8.2 DATA MODELING: ........... 36 3.9 TEAMS AND ANALYST CONTRIBUTION ................... 38 4 MARKET DYNAMICS ...... 40 4.1 INTRODUCTION ....................... 40 4.2 DRIVERS ............... 41 4.2.1 INCREASING ADOPTION OF HORMONAL THERAPIES FOR SYMPTOM MANAGEMENT ................ 41 4.2.2 INCREASING PREVALENCE OF ENDOMETRIOSIS ...... 41 4.2.3 GROWING USE OF COMBINATION AND LONG-TERM DRUG THERAPIES .......... 42 4.2.4 INCREASING TREATMENT UPTAKE FOR ENDOMETRIOSIS-ASSOCIATED PAIN AND INFERTILITY ........................... 43 4.3 RESTRAINTS ...... 44 4.3.1 HIGH TREATMENT COSTS AND LIMITED REIMBURSEMENT IN SOME REGIONS .................... 44 4.3.2 SIDE EFFECTS ASSOCIATED WITH HORMONAL THERAPIES ............ 44 4.3.3 LACK OF CURATIVE TREATMENTS AND HIGH DISEASE RECURRENCE ............. 45 4.4 OPPORTUNITIES ..................... 46 4.4.1 INCREASING INVESTMENT IN WOMEN’S HEALTH .......................... 46 4.4.2 EXPANSION OF PIPELINE DRUGS AND CLINICAL RESEARCH ......................... 47 5 MARKET FACTOR ANALYSIS .............. 48 5.1 REGULATORY ENVIRONMENT & COMPLIANCE ........................... 48 5.2 TECHNOLOGICAL TRENDS & INNOVATION .............. 50 5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ......................... 50 5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ................ 51 5.4.1 NORTH AMERICA ............ 51 5.4.2 EUROPE ....................... 51 5.4.3 ASIA PACIFIC ................ 51 5.4.4 REST OF THE WORLD ......... 52 5.4.5 REIMBURSEMENT DYNAMICS .................. 52 5.5 MARKET ENTRY & EXIT BARRIERS ...... 52 5.5.1 BARRIERS TO ENTRY .......... 52 5.5.2 BARRIERS TO EXIT ............ 53 5.6 PARTNERSHIPS & COLLABORATIONS ........................ 53 5.7 CONSUMER & HEALTHCARE PROVIDER PREFERENCES ........... 54 5.7.1 CONSUMER PREFERENCES ..................... 54 5.7.2 HEALTHCARE PROVIDER PREFERENCES ...................... 54 5.8 PESTLE ANALYSIS ................. 55 5.8.1 POLITICAL FACTORS ........................ 55 5.8.2 ECONOMIC FACTORS .......................... 55 5.8.3 SOCIAL FACTORS ....... 55 5.8.4 TECHNOLOGICAL FACTORS .............. 56 5.8.5 LEGAL FACTORS ........ 56 5.8.6 ENVIRONMENTAL FACTORS ............. 56 5.9 PORTER'S FIVE FORCES MODEL ............. 57 5.9.1 THREAT OF NEW ENTRANTS ..................... 57 5.9.2 BARGAINING POWER OF SUPPLIERS ....................... 58 5.9.3 THREAT OF SUBSTITUTES ........................ 58 5.9.4 BARGAINING POWER OF BUYERS .............. 58 5.9.5 INTENSITY OF RIVALRY ...... 58 5.10 PRODUCT PIPELINE ANALYSIS ............... 59 5.11 CASE STUDY ANALYSIS ...... 59 5.12 INVESTMENT & FUNDING SCENARIOS ...................... 60 5.13 POST-MARKET SURVEILLANCE & SAFETY DATA ...................... 61 5.14 DISEASE OVERVIEW ............. 62 5.15 DIAGNOSIS .......... 62 5.16 CURRENT TREATMENT ...... 63 6 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE ...... 66 6.1 OVERVIEW .......... 66 7 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY END USER .................... 69 7.1 OVERVIEW .......... 69 8 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY REGION ........................ 71 8.1 OVERVIEW .......... 71 8.2 NORTH AMERICA ................... 73 8.2.1 US ........ 76 8.2.2 CANADA ....................... 77 8.3 EUROPE ................ 78 8.3.1 GERMANY ..................... 81 8.3.2 UK ....... 82 8.3.3 FRANCE ........................ 83 8.3.4 NETHERLANDS ................ 84 8.3.5 ITALY ........................... 85 8.3.6 SPAIN ......................... 86 8.3.7 REST OF EUROPE ............ 87 8.4 ASIA PACIFIC ........................... 88 8.4.1 CHINA ......................... 91 8.4.2 INDIA .......................... 92 8.4.3 JAPAN ......................... 93 8.4.4 SOUTH KOREA ................ 94 8.4.5 MALAYSIA .................... 95 8.4.6 THAILAND ...................... 96 8.4.7 INDONESIA ................... 97 8.4.8 REST OF ASIA PACIFIC ...... 98 8.5 LATAM ................. 100 8.5.1 BRAZIL ......................... 103 8.5.2 MEXICO ....................... 104 8.5.3 ARGENTINA.................... 105 8.5.4 REST OF LATIN AMERICA ........................ 106 8.6 MIDDLE EAST AND AFRICA ...................... 107 8.6.1 GCC COUNTRIES......... 109 8.6.2 SOUTH AFRICA ........... 111 8.6.3 REST OF MIDDLE EAST AND AFRICA .......... 112 9 COMPETITIVE LANDSCAPE ................ 115 9.1 INTRODUCTION ....................... 115 9.2 MARKET SHARE ANALYSIS, 2025 ......... 115 9.3 COMPETITOR DASHBOARD....................... 116 9.4 PUBLIC PLAYERS STOCK SUMMARY ......................... 117 9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ............ 117 9.1 KEY DEVELOPMENTS & GROWTH STRATEGIES .......................... 118 9.1.1 PRODUCT APPROVAL ........ 118 10 COMPANY PROFILES .......................... 119 10.1 PFIZER INC. ......... 119 10.1.1 COMPANY OVERVIEW ....................... 119 10.1.2 FINANCIAL OVERVIEW ...................... 120 10.1.3 PRODUCTS OFFERED ........................ 121 10.1.4 KEY DEVELOPMENTS ........................ 121 10.1.5 SWOT ANALYSIS ........ 121 10.1.6 KEY STRATEGIES ........ 122 10.2 MEDTRONIC ....... 123 10.2.1 COMPANY OVERVIEW ....................... 123 10.2.2 FINANCIAL OVERVIEW ...................... 124 10.2.3 PRODUCTS OFFERED ........................... 125 10.2.4 KEY DEVELOPMENTS ........................ 125 10.2.5 SWOT ANALYSIS ........ 125 10.2.6 KEY STRATEGIES ........ 126 10.3 ASTRAZENECA........................ 127 10.3.1 COMPANY OVERVIEW ....................... 127 10.3.2 FINANCIAL OVERVIEW ...................... 128 10.3.4 KEY DEVELOPMENTS ........................ 128 10.3.5 KEY STRATEGIES ........ 129 10.4 F. HOFFMANN-LA ROCHE LTD. ............... 130 10.4.1 COMPANY OVERVIEW ...................... 130 10.4.2 FINANCIAL OVERVIEW ...................... 131 10.4.4 KEY DEVELOPMENTS ........................ 132 10.4.5 KEY STRATEGIES ........ 132 10.5 HALEON PLC ...... 133 10.5.1 COMPANY OVERVIEW ....................... 133 10.5.2 FINANCIAL OVERVIEW ...................... 134 10.5.4 KEY DEVELOPMENTS ........................ 135 10.5.5 KEY STRATEGIES ........ 135 10.6 ABBVIE INC. ........ 136 10.6.1 COMPANY OVERVIEW ....................... 136 10.6.2 FINANCIAL OVERVIEW ...................... 137 10.6.3 PRODUCTS OFFERED ...... 137 10.6.4 KEY DEVELOPMENTS ........................ 137 10.6.5 SWOT ANALYSIS ........ 138 10.6.6 KEY STRATEGIES ........ 139 10.7 BAYER AG ........... 140 10.7.1 COMPANY OVERVIEW ....................... 140 10.7.2 FINANCIAL OVERVIEW ...................... 142 10.7.3 PRODUCTS OFFERED ........................... 143 10.7.4 KEY DEVELOPMENTS ........................ 143 10.7.5 SWOT ANALYSIS ........ 144 10.7.6 KEY STRATEGIES ........ 145 10.8 SANOFI ................. 146 10.8.1 COMPANY OVERVIEW ....................... 146 10.8.2 FINANCIAL OVERVIEW ...................... 147 10.8.3 PRODUCTS OFFERED ...... 148 10.8.4 KEY DEVELOPMENTS ........................ 148 10.8.5 SWOT ANALYSIS ........ 148 10.8.6 KEY STRATEGY ............... 149 10.9 TEVA PHARMACEUTICAL INDUSTRIES LTD. .......... 150 10.9.1 COMPANY OVERVIEW ....................... 150 10.9.2 FINANCIAL OVERVIEW ...................... 151 10.9.3 PRODUCTS OFFERED ...... 152 10.9.4 KEY DEVELOPMENTS ........................ 152 10.9.5 KEY STRATEGIES ........ 153 10.10 SUN PHARMACEUTICAL INDUSTRIES LTD. ............. 154 10.10.1 COMPANY OVERVIEW ....................... 154 10.10.2 FINANCIAL OVERVIEW ...................... 155 10.10.3 PRODUCTS OFFERED ........................... 156 10.10.4 KEY DEVELOPMENTS ........................ 156 10.10.5 KEY STRATEGIES ........ 156 10.11 DATA CITATIONS ................... 157

圖表清單 List of Tables & Figures

LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 37 TABLE 2 NORTH AMERICA PRICING ANALYSIS, BY PRODUCT 51 TABLE 3 EUROPE PRICING ANALYSIS, BY PRODUCT 51 TABLE 4 ASIA PACIFIC PRICING ANALYSIS, BY PRODUCT 51 TABLE 5 REST OF THE WORLD PRICING ANALYSIS, BY PRODUCT 52 TABLE 6 PRODUCT PIPELINE 59 TABLE 7 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 67 TABLE 8 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2035 (USD MILLION) 68 TABLE 9 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, END USER, 2019-2035 (USD MILLION) 70 TABLE 10 GLOBAL ENDOMETRIOSIS MARKET, BY REGION, 2019-2035 (USD MILLION) 72 TABLE 11 NORTH AMERICA ENDOMETRIOSIS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 74 TABLE 12 NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 75 TABLE 13 NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2035 (USD MILLION) 75 TABLE 14 NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET, END USER, 2019-2035 (USD MILLION) 75 TABLE 15 US ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 76 TABLE 16 US ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2035 (USD MILLION) 76 TABLE 17 US ENDOMETRIOSIS TREATMENT MARKET, END USER, 2019-2035 (USD MILLION) 76 TABLE 18 CANADA ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 77 TABLE 19 CANADA ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2035 (USD MILLION) 77 TABLE 20 CANADA ENDOMETRIOSIS TREATMENT MARKET, END USER, 2019-2035 (USD MILLION) 77 TABLE 21 EUROPE ENDOMETRIOSIS TREATMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 79 TABLE 22 EUROPE ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 80 TABLE 23 EUROPE ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 80 TABLE 24 EUROPE ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 80 TABLE 25 GERMANY ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 81 TABLE 26 GERMANY ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 81 TABLE 27 GERMANY ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 81 TABLE 28 UK ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 82 TABLE 29 UK ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 82 TABLE 30 UK ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 82 TABLE 31 FRANCE ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 83 TABLE 32 FRANCE ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 83 TABLE 33 FRANCE ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 83 TABLE 34 NETHERLANDS ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 84 TABLE 35 NETHERLANDS ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 84 TABLE 36 NETHERLANDS ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 84 TABLE 37 ITALY ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 85 TABLE 38 ITALY ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 85 TABLE 39 ITALY ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 85 TABLE 40 SPAIN ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 86 TABLE 41 SPAIN ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 86 TABLE 42 SPAIN ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 86 TABLE 43 REST OF EUROPE ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 87 TABLE 44 REST OF EUROPE ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 87 TABLE 45 REST OF EUROPE ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 87 TABLE 46 ASIA PACIFIC ENDOMETRIOSIS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 89 TABLE 47 ASIA PACIFIC ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 90 TABLE 48 ASIA PACIFIC ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 90 TABLE 49 ASIA PACIFIC ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 91 TABLE 50 CHINA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 91 TABLE 51 CHINA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 91 TABLE 52 CHINA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 92 TABLE 53 INDIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 92 TABLE 54 INDIA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 92 TABLE 55 INDIA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 93 TABLE 56 JAPAN ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 93 TABLE 57 JAPAN ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 93 TABLE 58 JAPAN ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 94 TABLE 59 SOUTH KOREA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 94 TABLE 60 SOUTH KOREA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 94 TABLE 61 SOUTH KOREA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 95 TABLE 62 MALAYSIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 95 TABLE 63 MALAYSIA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 95 TABLE 64 MALAYSIA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 96 TABLE 65 THAILAND ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 96 TABLE 66 THAILAND ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 96 TABLE 67 THAILAND ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 97 TABLE 68 INDONESIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 97 TABLE 69 INDONESIA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 97 TABLE 70 INDONESIA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 98 TABLE 71 REST OF ASIA PACIFIC ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 98 TABLE 72 REST OF ASIA PACIFIC ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 99 TABLE 73 REST OF ASIA PACIFIC ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 99 TABLE 74 LATAM ENDOMETRIOSIS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 101 TABLE 75 LATAM ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 102 TABLE 76 LATAM ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 102 TABLE 77 LATAM ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 102 TABLE 78 BRAZIL ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 103 TABLE 79 BRAZIL ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 103 TABLE 80 BRAZIL ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 103 TABLE 81 MEXICO ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 104 TABLE 82 MEXICO ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 104 TABLE 83 MEXICO ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 105 TABLE 84 ARGENTINA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 105 TABLE 85 ARGENTINA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 105 TABLE 86 ARGENTINA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 106 TABLE 87 REST OF LATIN AMERICA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 106 TABLE 88 REST OF LATIN AMERICA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 106 TABLE 89 REST OF LATIN AMERICA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 107 TABLE 90 MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 108 TABLE 91 MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 108 TABLE 92 MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 109 TABLE 93 MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 109 TABLE 94 GCC COUNTRIES ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 109 TABLE 95 GCC COUNTRIES ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 110 TABLE 96 GCC COUNTRIES ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 110 TABLE 97 SOUTH AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 111 TABLE 98 SOUTH AFRICA ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 111 TABLE 99 SOUTH AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 111 TABLE 100 REST OF MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 112 TABLE 101 REST OF MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 112 TABLE 102 REST OF MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 113 TABLE 103 PRODUCT APPROVAL 118 TABLE 104 PFIZER INC.: PRODUCTS OFFERED 121 TABLE 105 PFIZER INC.: KEY DEVELOPMENTS 121 TABLE 106 MEDTRONIC: SERVICES OFFERED 125 TABLE 110 ABBVIE, INC.: PRODUCTS OFFERED 137 TABLE 111 BAYER AG: PRODUCT OFFERED 143 TABLE 112 SANOFI.: PRODUCTS OFFERED 148 TABLE 113 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED 152 TABLE 114 SUN PHARMACEUTICAL INDUSTRIES LTD. : PRODUCT OFFERED 156 LIST OF FIGURES FIGURE 1 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL ENDOMETRIOSIS TREATMENTMARKET, 2025 18 FIGURE 2 GLOBAL ENDOMETRIOSIS TREATMENTMARKET ANALYSIS, BY TREATMENT TYPE, 2025 (USD MILLION AND %) 19 FIGURE 3 GLOBAL ENDOMETRIOSIS TREATMENTMARKET ANALYSIS, BY END USE, 2025 (USD MILLION AND %) 20 FIGURE 1 GLOBAL ENDOMETRIOSIS MARKET: STRUCTURE 23 FIGURE 2 GLOBAL ENDOMETRIOSIS MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2035) 41 FIGURE 3 GLOBAL ENDOMETRIOSIS MARKET DRIVER: IMPACT ANALYSIS 43 FIGURE 4 GLOBAL ENDOMETRIOSIS MARKET RESTRAINT: IMPACT ANALYSIS 45 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ENDOMETRIOSIS TREATMENT MARKET 57 FIGURE 6 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, TREATMENT TYPE SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 66 FIGURE 7 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2025 & 2035 (USD MILLION) 67 FIGURE 8 GLOBAL ENDOMETRIOSIS TREATMENT MARKET SHARE (%), BY TREATMENT TYPE, 2025 68 FIGURE 9 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, END USER SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 69 FIGURE 10 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY END USER, 2025 & 2035 (USD MILLION) 70 FIGURE 11 GLOBAL ENDOMETRIOSIS TREATMENT MARKET SHARE (%), BY END USER, 2025 70 FIGURE 12 GLOBAL ENDOMETRIOSIS MARKET, BY REGION, 2025 & 2035 (USD MILLION) 71 FIGURE 13 GLOBAL ENDOMETRIOSIS MARKET SHARE (%), BY REGION, 2025 72 FIGURE 14 NORTH AMERICA ANALYSIS: ENDOMETRIOSIS MARKET, 2019-2035 (USD MILLION) 73 FIGURE 15 NORTH AMERICA MARKET ANALYSIS: ENDOMETRIOSIS TREATMENT MARKET, 2019-2035 (USD MILLION) 73 FIGURE 16 NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 74 FIGURE 17 EUROPE ANALYSIS: ENDOMETRIOSIS MARKET, 2019-2035 (USD MILLION) 78 FIGURE 18 EUROPE MARKET ANALYSIS: ENDOMETRIOSIS TREATMENT MARKET, 2019-2035 (USD MILLION) 78 FIGURE 19 EUROPE ENDOMETRIOSIS TREATMENT MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 79 FIGURE 20 ASIA PACIFIC: SWOT ANALYSIS 88 FIGURE 21 ASIA PACIFIC ENDOMETRIOSIS MARKET, BY REGION, 2025 & 2035 (USD MILLION) 89 FIGURE 22 ASIA PACIFIC ENDOMETRIOSIS MARKET SHARE (%), BY COUNTRY, 2025 90 FIGURE 23 LATAM: SWOT ANALYSIS 100 FIGURE 24 LATAM ENDOMETRIOSIS MARKET, BY REGION, 2025 & 2035 (USD MILLION) 100 FIGURE 25 LATAM ENDOMETRIOSIS MARKET SHARE (%), BY COUNTRY, 2025 101 FIGURE 26 MIDDLE EAST AND AFRICA MARKET ANALYSIS: ENDOMETRIOSIS TREATMENT MARKET, 2019-2035 (USD MILLION) 107 FIGURE 27 MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 108 FIGURE 28 GLOBAL ENDOMETRIOSIS TREATMENT MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 115 FIGURE 29 COMPETITOR DASHBOARD: GLOBAL ENDOMETRIOSIS TREATMENT MARKET 116 FIGURE 30 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 120 FIGURE 31 PFIZER INC.: SWOT ANALYSIS 121 FIGURE 32 MEDTRONIC: FINANCIAL OVERVIEW SNAPSHOT 124 FIGURE 33 MEDTRONIC: SWOT ANALYSIS 125 FIGURE 34 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 128 FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT 131 FIGURE 36 HALEON PLC: FINANCIAL OVERVIEW SNAPSHOT 134 FIGURE 37 ABBVIE, INC.: FINANCIAL OVERVIEW SNAPSHOT 137 FIGURE 38 ABBVIE, INC.: SWOT ANALYSIS 138 FIGURE 39 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 142 FIGURE 40 BAYER AG : SWOT ANALYSIS 144 FIGURE 41 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 147 FIGURE 42 SANOFI: SWOT ANALYSIS 148 FIGURE 43 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 151 FIGURE 44 SUN PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 155

Single User Price	$4,950 USD
Multi User Licence (up to 10 users)	$5,950 USD
Enterprisewide Price (Global Site License)	$7,250 USD

授權報價

報告摘要

提及公司

同分類最新報告（醫療與生命科學）